Dose topiramate for reassement epilepsy withdrawal symptoms on noncomplience patient
Topiramate has shown efficacy in managing refractory epilepsy. In patients with drug-resistant partial epilepsy, topiramate as an add-on treatment demonstrated a 50% or greater reduction in seizure frequency compared to placebo, with an overall odds ratio of 4.06 (95% CI: 2.86-5.78). However, withdrawal from treatment due to side effects was observed, with fatigue, weight loss, irritability, and other adverse events leading to discontinuation in some cases. Notably, topiramate doses above 400 mg per day did not show added advantage in efficacy, indicating that lower doses may be sufficient for many patients. Therefore, when reassessing epilepsy treatment in non-compliant patients, considering lower doses of topiramate may be beneficial to balance efficacy and tolerability.
Answers from top 5 papers
Papers (5) | Insight |
---|---|
72 Citations | Not addressed in the paper. |
27 Citations | Topiramate at 200mg daily is effective with fewer withdrawals due to adverse events, making it a suitable dose for managing partial epilepsy with good compliance. |
Not addressed in the paper. | |
35 Citations | Topiramate withdrawal symptoms due to noncompliance in refractory epilepsy patients included ataxia, somnolence, metabolic acidosis, irritability, and psychotic symptoms, leading to treatment discontinuation in some cases. |
Not addressed in the paper. |